Pushing boundaries, staying grounded, and having fun along the way are the key ingredients for success in biotech, writes ...

Biotech companies that will lead the next decade wont just have better science, theyll have superior operating models, writes ...

Life sciences organizations are highly visible and active across established media channels, but discoverability represents ...

The False Claims Act (FCA) and the Anti-Kickback Statute (AKS) are two of the Department of Justice’s (DOJ) primary tools when it comes to fighting fraud. Originally enacted during the Civil War to ...

On this week's episode of the Business of Biotech, we're speaking with Kenneth Galbraith, CEO and Board Chair at Zymeworks, a biotech developing multispecific therapies internally and through ...

In a complex global and competitive world, formulating a plan without testing it against likely external reactions is the equivalent of walking into a battlefield without the right weapons or a plan ...

Spinning off a $4 billion biopharma business is no easy task. Integrated functions need to be separated, governance boards created, leadership teams assembled, and corporate headquarters established.

“THAT WAS A TERRIFYING MOMENT,” reflects Matt Patterson, cofounder, chairman, and CEO of Audentes Therapeutics, a genetic medicines company focused on the adeno-associated virus (AAV). It was the fall ...

In the rapidly evolving world of life sciences, companies are constantly seeking ways to optimize their business structures to better navigate the complex landscape of drug development and financing.

Since the start of his second term, President Trump has shown a clear commitment to improving access to medicines for American patients. In late September 2025, his Administration reaffirmed this ...

A substantial share of biopharmaceutical drug launches (>50%) fail to meet their projected analyst forecasts (see also Simon-Kucher Biotech industry study 2019). With considerable investment going ...

Since clinical trials have become increasingly complex with more data being collected, this consequently puts more pressure on sponsors to improve efficiencies while still maintaining quality.